Krystal Biotech, Inc.

Krystal Biotech, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Krystal Biotech, Inc. has 29.60M shares outstanding.

As of June 30, 2026, Krystal Biotech, Inc. maintains a current ratio of 8.32, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. posted a return on equity (ROE) of 20.12, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 18.30, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.33M in revenue per employee across its workforce of 290.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.62 indicates how many times Krystal Biotech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. recorded an income tax benefit of -12.99M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 198.36M, leaving 211.35M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. generated 385.56M in revenue and converted that into 211.35M in net income, yielding earnings per share of 6.97. EBITDA reached 178.93M, while operating income came in at 173.09M.

As of June 30, 2026, Krystal Biotech, Inc. holds 740.18M in cash and equivalents against 7.75M in total debt, resulting in a net debt position of -374.40M. Total book value stands at 1.19B, with working capital of 816.00M providing operational flexibility.

Krystal Biotech, Inc. produced 238.38M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.74M in capital expenditures, free cash flow totaled 225.64M - equivalent to 7.72 per share.

Over the twelve months ended June 30, 2026, Krystal Biotech, Inc. posted a gross margin of 94.64, reflecting its pricing power and cost economics. The operating margin of 44.89 and net profit margin of 54.82 provide insight into operational efficiency.